TP53 and ovarian cancer: While intratumoral injections in subcutaneous models may have succeeded, an in vivo study with adenovirus-carrying WT p53 delivered intraperitoneally for ovarian cancer with p53 mutation failed to produce a significant difference in the survival outcome [110].